Form 4: Enliven Therapeutics Director Receives Stock Grant
Insider Transaction (Form 4)
Kristine M Ball, a Director of Enliven Therapeutics, Inc., received 23,394 shares of common stock on October 14, 2026.
Summary
- Grant/award: acquired 23,394 Stock Option (right to buy) on October 14, 2026; holds 23,394 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Kristine M Ball — Director
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-10-14 | Grant/award | Stock Option (right to buy) | 23,394 | — | — | 23,394 |
Key Dates
| Date | Description |
|---|---|
| 2026-10-14 | Grant/award (23,394 shares) |
Keywords
insider transaction, Form 4, ELVN, Enliven Therapeutics, Inc., neutral, Kristine M Ball
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.